BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, Makhson A, Tjulandin S, Ludwig H, Verrill M. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol. 2009;27:526-534. [PMID: 19075286 DOI: 10.1200/jco.2007.14.2646] [Cited by in Crossref: 79] [Cited by in F6Publishing: 26] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Rak Tkaczuk KH. Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer. Breast Cancer (Auckl) 2011;5:1-14. [PMID: 21494397 DOI: 10.4137/BCBCR.S5331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Cristofanilli M. Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone. J Oncol 2012;2012:703858. [PMID: 22645612 DOI: 10.1155/2012/703858] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
3 Moiseenko F, Volkov N, Bogdanov A, Dubina M, Moiseyenko V. Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion. F1000Res 2017;6:288. [PMID: 28751966 DOI: 10.12688/f1000research.10992.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
4 Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8:1913-24. [PMID: 27765921 DOI: 10.18632/oncotarget.12284] [Cited by in Crossref: 143] [Cited by in F6Publishing: 127] [Article Influence: 47.7] [Reference Citation Analysis]
5 Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract 2011;2011:696208. [PMID: 22312556 DOI: 10.1155/2011/696208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
6 De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 2010;28:149-53. [PMID: 19917861 DOI: 10.1200/JCO.2009.24.1455] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
7 Fountzilas G, Kotoula V, Pectasides D, Kouvatseas G, Timotheadou E, Bobos M, Mavropoulou X, Papadimitriou C, Vrettou E, Raptou G, Koutras A, Razis E, Bafaloukos D, Samantas E, Pentheroudakis G, Skarlos DV. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One 2013;8:e69256. [PMID: 23935969 DOI: 10.1371/journal.pone.0069256] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Gradishar W. Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des Devel Ther 2009;3:163-71. [PMID: 19920932 DOI: 10.2147/dddt.s3122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
9 Ott PA, Hamilton A, Jones A, Haas N, Shore T, Liddell S, Christos PJ, Doyle LA, Millward M, Muggia FM, Pavlick AC. A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One 2010;5:e8714. [PMID: 20098694 DOI: 10.1371/journal.pone.0008714] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G, Pusztai L. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. Oncologist 2013;18:787-94. [PMID: 23853246 DOI: 10.1634/theoncologist.2013-0075] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
11 Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL; FEMME Consortium. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010;4:209-29. [PMID: 20537966 DOI: 10.1016/j.molonc.2010.04.006] [Cited by in Crossref: 181] [Cited by in F6Publishing: 174] [Article Influence: 16.5] [Reference Citation Analysis]
12 Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319-1329. [PMID: 19535820 DOI: 10.1093/annonc/mdp322] [Cited by in Crossref: 980] [Cited by in F6Publishing: 765] [Article Influence: 81.7] [Reference Citation Analysis]
13 Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. J Oncol 2013;2013:219869. [PMID: 23983689 DOI: 10.1155/2013/219869] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
14 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
15 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
16 Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer 2013;2013:137414. [PMID: 23864953 DOI: 10.1155/2013/137414] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 10.6] [Reference Citation Analysis]
17 Moen MD. Ixabepilone: in locally advanced or metastatic breast cancer. Drugs 2009;69:1471-81. [PMID: 19634925 DOI: 10.2165/00003495-200969110-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106-116. [PMID: 26175926 DOI: 10.7497/j.issn.2095-3941.2015.0030] [Cited by in F6Publishing: 148] [Reference Citation Analysis]
19 Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010;12 Suppl 2:S3. [PMID: 21050424 DOI: 10.1186/bcr2574] [Cited by in Crossref: 136] [Cited by in F6Publishing: 133] [Article Influence: 12.4] [Reference Citation Analysis]
20 Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10:194-204. [PMID: 20147901 DOI: 10.1038/nrc2803] [Cited by in Crossref: 638] [Cited by in F6Publishing: 565] [Article Influence: 58.0] [Reference Citation Analysis]
21 Egerton N. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. Cancer Chemother Pharmacol 2010;66:1005-12. [PMID: 20886213 DOI: 10.1007/s00280-010-1467-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
22 Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010;3:42. [PMID: 20979652 DOI: 10.1186/1756-8722-3-42] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
23 Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol 2010;7:139-47. [PMID: 20125090 DOI: 10.1038/nrclinonc.2009.234] [Cited by in Crossref: 120] [Cited by in F6Publishing: 97] [Article Influence: 10.9] [Reference Citation Analysis]
24 Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, Fornier MN, Martín M, Bunnell CA, Mukhopadhyay P, Peck RA, Perez EA. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer 2012;20:2661-8. [PMID: 22382588 DOI: 10.1007/s00520-012-1384-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
25 Amos KD, Adamo B, Anders CK. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer 2012;2012:385978. [PMID: 22461984 DOI: 10.1155/2012/385978] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
26 Ibrahim NK. Ixabepilone development across the breast cancer continuum: a paradigm shift. Cancer Manag Res 2010;2:169-79. [PMID: 21188108 DOI: 10.2147/cmar.s10570] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]